Ingredion Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all director nominees, executive compensation, and auditor ratification. Management addressed questions on earnings disclosures, GLP-1 market impacts, and geopolitical risks, highlighting supply chain resilience and long-term growth opportunities.
-
Q1 2026 saw a 1% sales decline and a 22% drop in adjusted operating income, mainly due to Argo facility issues and softer volumes in F&II U.S. Canada and LATAM. T&HS delivered its eighth straight quarter of volume growth, while full-year guidance was revised downward amid ongoing macro and FX headwinds.
-
Record 2025 results were driven by innovation in texture, clean label, and private label solutions, with strong growth in LATAM and U.S./Canada. Strategic investments in AI, capacity, and productivity underpin a 2025-2028 outlook of mid-single digit OI growth and >10% TSR.
Fiscal Year 2025
-
Record operating income and EPS growth were achieved despite operational setbacks and industry softness, with strong performance in Texture and Healthful Solutions and LATAM. 2026 guidance calls for modest sales and income growth, with continued investment in innovation and productivity.
-
Q3 saw net sales and operating income decline more than expected due to operational and macroeconomic challenges, but full-year income growth is still forecast. Texture & Healthful Solutions outperformed, while U.S./Canada and LATAM segments faced headwinds from plant disruptions and weak demand.
-
A comprehensive transformation has positioned the company as a global solutions provider, driving growth through innovation, operational excellence, and disciplined capital allocation. New long-term targets focus on margin expansion, segment-specific growth, and leveraging AI-driven R&D, with a strong balance sheet supporting both organic and M&A-driven investments.
-
Record Q2 adjusted operating income was achieved despite lower net sales, with strong growth in Texture and Healthful Solutions and margin expansion. Guidance for 2025 was raised, but macroeconomic and tariff uncertainties persist, especially in LATAM and industrial starch segments.
-
The meeting highlighted a successful 2024 with strong profit growth, a new business structure, and robust returns to stockholders. All board nominees, executive compensation, and auditor ratification proposals passed by majority vote.
-
Double-digit adjusted EPS and operating income growth in Q1 2025 were driven by strong sales in texture and healthful solutions, margin expansion, and operational execution. Full-year guidance is maintained, with minimal tariff impact expected and continued focus on cost management and capital allocation.
Fiscal Year 2024
-
Double-digit adjusted EPS growth in Q4 and record gross margins in 2024 were driven by strong performance in Texture and Healthful Solutions and operational excellence. 2025 guidance anticipates continued sales and income growth, with elevated CapEx for strategic investments and ongoing cost-saving initiatives.
-
A global leader in texture and healthful solutions is leveraging innovation, consumer insights, and advanced ingredient science to drive growth in a $20 billion market. The segment targets 5%-6% sales CAGR and margin expansion, supported by clean label trends, affordability, and strong R&D investment.
-
Q3 saw record adjusted operating income and double-digit growth across all segments, driven by operational excellence, contract management, and strong demand for differentiated solutions. Full-year guidance was raised for adjusted EPS and cash flow, with continued focus on cost savings, capital returns, and strategic investments.
-
Q2 2024 saw record profitability with 8% adjusted operating income growth and a 240 bps gross margin increase, despite a 9% sales decline. Strong volume recovery, cost controls, and lower input costs drove results, with full-year guidance raised for adjusted EPS and cash flow.